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HIV-1 integrase (IN)hasbecomeanattractive target sincedrug resistance againstHIV-1 reverse transcrip-
tase (RT) and protease (PR) has appeared. Diketo acid (DKA) inhibitors are potent and selective inhibitors
of HIV-1 IN: however the action mechanism is not well understood. Here, to study the inhibition mech-
anism of DKAs we performed 10ns comparative molecular dynamics simulations on HIV-1 IN bound
with three most representative DKA inhibitors: Shionogi inhibitor, S-1360 and two Merck inhibitors
L-731,988 and L-708,906. Our simulations show that the acidic part of S-1360 formed salt bridge andIV-1 integrase
iketo acid inhibitors
olecular dynamics
on–pair interaction
atalytic loop
cation– interactions with Lys159. In addition, the catalytic Glu152 in S-1360 was pushed away from
the active site to form an ion–pair interaction with Arg199. The Merck inhibitors can maintain either one
or both of these ion–pair interaction features. The difference in potencies of the DKA inhibitors is thus
attributed to the different binding modes at the catalytic site. Such structural information at atomic level,
not only demonstrates the action modes of DKA inhibitors but also provides a novel starting point for
structural-based design of HIV-1 IN inhibitors.. Introduction
The human immunodeﬁciency virus type 1 (HIV-1) encodes
hree enzymes: reverse transcriptase (RT), protease (PR), and inte-
rase (IN). With the emerging drug-resistance of the ﬁrst two
argets, it is urgent to develop potent inhibitors for the third tar-
et, IN [1–5]. IN is involved in the viral replication process which
ndergoes two separate reactions. In the ﬁrst step, IN processes the
iral DNA by removing a conserved dinucleotide from each 3′ end,
ermed 3′-processing. Then the processed viral DNA is linked to the
ost cell DNA; the so-called strand transfer reactions [6].
HIV-1 IN is composed of three functional domains. The N-
erminal domain is comprised of residues 1–50 and the catalytic
omain comprises amino acids 50–212. The C-terminal domain,
hich comprises residues 212–288was suggested to serve in bind-
ng the viral DNA during the integration process [7]. Each domain
an form dimers and full-length IN is known to act as a multimer
8,9]. Although the respective domain structure has been disclosed,
he full length protein has not been resolved. The catalytic domain
ontains three conserved amino acids, Asp64, Asp116 and Glu152
Fig. 1), comprising aDDEmotif,which is also present in otherDNA-
rocessing enzymes such as ASV [10], RHase and Tn5 [11]. In the IN
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catalytic domain an Mg ion is coordinated to the oxygen atoms of
Asp64 and Asp116. It has been suggested that a second metal ion,
coordinated to Glu152 and Asp64, is present when binding with
the DNA substrate [12,13], although the exact location of the sec-
ondMg is not known. Aﬂexible loop, comprising residues 138–149,
is known to be crucial for the catalytic activity of HIV integrase [14]
and amino acids Lys156, Lys159, Tyr143 and Gln148 are implicated
in the binding of viral DNA [15,16].
Among the emerging HIV-1 IN inhibitors, 4-aryl-2,4-
dioxobutanoic acid derivatives were found to have potent
inhibitory activity on strand transfer. Two representative com-
pounds are L-731,988 and L-708,906 [17] (Fig. 2) from Merck.
S-1360 [18], a potent IN inhibitor fromShionogi, also belongs to the
diketo acid inhibitor family because the trizole part of S-1360 can
be regarded as bioisostere of carboxlate (Fig. 2). It failed at phase
II clinical trial due to rapid metabolism. Individual or combined
mutationof T66I,M154I andS153Y confers resistance for theMerck
inhibitors [17] and themutation of N155S displays cross-resistance
for the Merck inhibitors and L-870,810 [19] (a potent strand trans-
fer inhibitor of IN which was derived from pharmacophore search
based on the DKA inhibitors but also failed at clinical trial). Nine
combinedmutationswhich include T66I, Q146K, S153A and others,
Open access under CC BY license.all confer resistance to S-1360, indicating that these compounds
bind at, or near, the enzyme active site [20]. Two DKA derivatives
Raltegravir (MK-0518) [21] and Elvitegravir (GS-9137) have been
recently approved as anti-AIDS drug or in clinical trials [22]. Q148K
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gig. 1. Ribbon diagram of HIV-1 IN (bound with 5-ClTEP). The catalytic DDE triad
nd ligand 5-ClTEP are shown in ball-and-stick representation. The ﬂexible loop
egion (residues 138-149) is shown in red.
nd T66I conferred the highest resistance to both drugs while
153Y conferred relatively greater resistance to Elvitegravir than
altegravir [23]. Mutation of Tyr143 is known to confer resistance
o Raltegravir [24]. The drug resistance to Raltegravir conferred by
utation of N155H, was attributed to the disruption of the metal
ofactors with the catalytic carboxylate at the active centre of IN
25]. The mutations of IN which confer resistance to DKA inhibitors
nd the derivative drugs are listed in Table S1.
The ﬁrst HIV-1 IN inhibitor complex solved (PDB code: 1QS4
26]) contains a Shionogi inhibitor 5-ClTEP, 1-(5-chloroindol-3-yl)-
-hydroxy-3-(2H-tetrazol-5-yl)-propenone (Fig. 1). The inhibitor
-ClTEP in HIV-1 IN is found to stabilize the ﬂexible loop. In the
arch issue of Nature 2010, the crystal structure of full length
ig. 2. The structures of 5-ClTEP, L-731,988, L-708,906, L-731,927, L-731,942, S-1360, Ra
roup of L-731,988 are labeled by arrows.ics and Modelling 29 (2011) 956–964 957
prototype foamy virus (PFV) IN in complex with DNA and strand
transfer inhibitors Raltegravir andElvitegravir [27]was reportedby
Peter Cherepanov. Recently resolvedNMRsolution conformationof
HIV-1 IN disclosed strikingly similarity to the crystal structure of
the PFV bound to DNA [28]. However, the HIV-1 IN-DNA structures
in presence of the DKA inhibitors such as the Merck Inhibitors and
S-1360 have not been resolved.
Computational modelling has been applied to investigate the
structures of HIV-1 IN-inhibitor complexes. Docking studies on IN
showed that the position of the 5-ClTEP may be affected by crys-
tal packing effects [29]. Flexible docking was performed by Keseru
and Kolossvary on 5-ClTEP and L-731,988 [30]. In the past several
years, molecular dynamics simulations have been applied to the
native and mutated IN [31–33] and IN in complex with 5-ClTEP
and a Merck inhibitor L-731,988 [34–37]. Hybrid QM/MM methods
were also used to investigate the dynamic behaviour of 5-ClTEP and
DKA bound IN [38–41].
Until now,adetailed interactionmechanismbetween thepotent
DKA inhibitors and the IN has not yet been completely elucidated,
due to unavailability of crystal structures of the IN complexes. In
addition, the conformational change which may be associated with
DKA binding makes it more complicated to understand the inter-
action modes. Molecular dynamics simulation is a powerful tool to
study the conformational change induced by bound ligands. In the
present work, we used ab initio calculations to prepare the param-
eters for the most representative DKA inhibitors; Merck inhibitors
L-731,988 and L-708,906, and S-1360.We then performed compar-
ative molecular dynamics simulations of IN in complex with these
compounds. The aim of the present work was to explore the bind-
ing modes of these representative DKA inhibitors and the induced
ﬁt effect of binding on the INprotein structure. Of particular focus is
the ﬂexible loop, which is close to the active site. This will uncover
structural information for use in structural-based drug design. To
our knowledge, our work is the ﬁrst to compare the binding modes
of the representative DKA inhibitors for HIV-1 IN by molecular
dynamics simulations.
ltegravir and Elvitegravir. 1 and 2 represent the rotations around the methylene
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.1. Minimum conformations of the L-731,988 anion
The tautomeric forms for the anion of L-731,988 were calcu-
ated using the B3LYP/6-31G* method with Gaussian 98 software
42]. Two dihedral rotations around the methylene group of the
romatic part were studied by the potential surface calculated
t the HF/STO-3G level followed by single point energy calcu-
ations with B3LYP/6-31G* method. The minima obtained were
ubjected to further optimization at the same level, B3LYP/6-31G**
nd B3LYP/6-31+G**, followed by a single point energy calculation
ith B3LYP/6-311+G (3df, 2p).
.2. Building the IN complex structures
The residues Ile141-Asn144arenotdetermined in the IN-5ClTEP
rystal structure (pdb code: 1QS4 [26]) and are only available in
wo other core domain structures [43,44]. To avoid potential arti-
act caused by induced ﬁt of ligand binding in the crystal structure
f IN bound with 5-ClTEP, the complete core domain of apo IN (pdb
ode: 1BIS (monomer B)) was used to build the IN in complex with
he DKA compounds. Only one metal Mg ion was included in MD
imulation, since the position of the second metal ion has not been
esolved and it was suggested it may only exist when IN is bound
ith DNA substrate [12,13]. The Mg ion is built based on the posi-
ion of Mg in the crystal structure of IN bound with 5-ClTEP. The
inimum-energy conformers of the L-731,988 anion were initially
ocked into the active site of IN, based on the DKA binding model
ypothesized by Grobler et al. [12] and also the molecular model
here DKA is bound in IN-DNA complex [13] (i.e., the keto–enol
xygen atoms of the DKA inhibitors are coordinated to the Mg ion
n our initial models).
We prepared two complex models in which the diketo part of
-731,988 was orientated in two different ways. In the ﬁrst model,
he complex structureswere built according to theposition andori-
ntation of 5-ClTEP in the crystal structure, with the enol and keto
xygen atoms of the inhibitor coordinated to the Mg ion. We also
uilt a model where two crystal waters (water 44 and 443) coor-
inated to Mg in the crystal structure of IN-5-ClTEP complex were
eplaced by the enol and carboxylic oxygen atomsof L-731,988. The
arbonyl oxygen of L-731,988 was positioned to interact with the
utative second Mg ion between Asp64 and Glu152. The models of
N in complexwith anotherMerck inhibitor L-708,906andShionogi
nhibitor S-1360 were built by superimposing the keto–enol part
f these compounds with that of L-731,988.
.3. Molecular dynamics simulation
Molecular dynamics was run with Charmm [45] (version 33b4,
arvard, Cambridge, MA) using the charmm27 force ﬁeld [46].
he force ﬁeld parameters for the ligands were obtained by HF/6-
1G* calculation. All crystal water were deleted, polar hydrogen
toms were added according to pKa prediction using the electro-
tatics potential calculation tool Delphi [47], in Biopolymermodule
f InsightII package (Accelrys, San Diego, CA). Based on the pKa
alculation, no unusual ionization states were found for the titrat-
ble groups (Asp, Glu, Arg, Lys, His, Tyr, Cys and N-ter and C-ter).
he hydrogen atoms were minimized with 500 steps of Steepest
escent (SD) optimization; TIP3P water [48] was added in a sphere
ith a radius of 25 A˚ around the reaction centre (theMg ion). Beforehe unconstrained MD simulation, the solvent was subjected to
000 steps of SDminimization, and equilibrated for 2.5ps at 1000K
ith solute ﬁxed. The system was then cooled to 300K and the
olvent was equilibrated for additional 15ps.ics and Modelling 29 (2011) 956–964
MD simulations were performed with a stochastic boundary
(SB) setup [49]. Atoms within the sphere of 21 A˚ (the reaction
region)were subjected to a conventionalNewtonian dynamics, and
atoms in the buffer region (a shell between spheres of radii 21 A˚ and
25 A˚)were treated by Langevin dynamics. Atoms outsidewere kept
ﬁxed. The friction coefﬁcients of 62ps were applied to the water
oxygens and the system was equilibrated at 300K for 17.5ps using
a time step of 1 fs; the SHAKE algorithm was used to constrain all
bonds involving hydrogen atoms. The production simulation was
carried out for 10,000ps (10ns). Snapshots of the trajectory were
taken every 0.25ps. To obtain the most representative frame from
the MD simulations, the average conformation was calculated. This
was achieved by averaging the snapshots of the last 500ps, then
choosing a typical structure with the lowest RMSD to the aver-
age conformation, and using this in binding mode analysis. This
structure was further minimized by Charmm force ﬁeld.
3. Results and discussion
3.1. The optimal conformations of 5-ClTEP and L-731,988
The tautomeric conformations of the anionic forms of 5-ClTEP
and L-731,988 were considered, starting from their stable neutral
enol forms [50]. Given the acidic nature of these compounds (pKa
is 5 for the tetrazole of 5-ClTEP and 4 for the carboxylic group of L-
731,988 [17]), their anionic forms were chosen for the simulation.
From our previous calculations for 5-ClTEP and L-731,988 [50], the
tautomerwith the enol group attached to the carboxylate/tetrazole
grouphas a lower energy than the onewith the enol group attached
to the pyrrol ring. Because L-708,906 and S-1360 have either a
carboxylate or heterozolate acidic group, analogous to L731,988
and 5-ClTEP, respectively, we deemed that they also exist in the
tautomeric form with enol connected to the acidic group.
There are two rotatable bonds around the methylene group of
the L-731,988 anion, 1 (C12C7C6N2) and 2 (C7C6N2N1) (Fig. 2).
Scanning of these two rotatable bondswith theHF/STO-3Gmethod
followed by single point energy calculation with B3LYP/6-31G*,
gave two minima including a pair of s-cis extended isomers (The
pyrrol nitrogen is in the cis position of the keto of the diketo acid
part, with  1 of ∓104.5◦ and  2 ±72.2◦) and a pair of s-trans folded
isomers ( 1 of ∓62.1◦ and  2 ±105.5◦) (Fig. 3). The energy of the
s-cis isomer is lower than the s-trans by 1.43kcalmol−1. Optimiza-
tionwithbiggerbasis setsB3LYP/6-31G**andB3LYP/6-31+G**gave
similar energy differences (1.43 and 1.96kcalmol−1, respectively).
Single point energy calculations at high level B3LYP/6-311+G (3df,
2p) based on the B3LYP/6-31+G** optimized geometries were
carried out. The relative energy difference remains the same
(1.55kcalmol−1). The lower energy of s-cis isomers by DFT calcu-
lation with different basis set aforementioned indicated that they
are more stable than the s-trans isomers. Both conformations were
used to build the starting internal geometries of the IN-L-731,988
complex.
3.2. Mg ion chelation
In the crystal structure of core domain IN in complex with 5-
ClTEP, the Mg ion was coordinated to two of the catalytic triad
residues, Asp64, and Asp116, and four water molecules. Over the
entire simulation of IN in complex with Merck inhibitors or S-
1360 (built based on the position and orientation of 5-ClTEP in
the crystal structure of IN complex), the carboxylic group of the
inhibitorsmaintained coordinationwith theMg ion. Two structural
waters were identiﬁed, unveiling an octahedral coordination with
the Mg ion together with the keto–enol part of the DKA inhibitors
and two catalytic triad residues; Asp64 and Asp116 (Supporting
information, Fig. S1).
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Big. 3. The minimum energy conformations of L-731,988 anions calculated by
3LYP/6-31G* method. a and b are isomers with identical absolute values of  1
nd  2.
That the keto–enol part of DKA inhibitorswas consistently coor-
inated to theMg ion supports thehypothesis thatDKAcompounds
nhibit IN by chelating with the metal cofactor [12]. HIV-1 IN is
ighly conserved with PFV IN at the active site [27]. In the crystal
tructures of PFV IN bound with two HIV-1 IN drugs, Raltegravir
nd Elvitegravir, the keto–enol part of these drugs are coordinated
o the Mg ion (Fig. S2). Thus, metal chelating modes of DKA com-
ounds is also commensurate with the binding modes of HIV-1 IN
rugs with PFV IN, Therefore, the analysis for the MD simulation
ereafter will be based on this model.
.3. Dynamic behaviour of the DKA bound IN complexes
The overall structural ﬂuctuation was evaluated by analyz-
ng the RMSDs of C atom versus simulation time (Fig. 4). All
KA-bound IN complexes reach equilibrium after 5000ps and
aintained at equilibrium for 5000ps, indicating the systems
volved into stable states and have reasonably converged.
.4. Opening of an additional hydrophobic cavity by L-708,906
We examined the surface around the IN active site where IN is
ound with DKA inhibitors. The central pyridine ring of L-731,988
s involved in hydrophobic interactions with Ile141. The aromatic
arts of L-731,988 form hydrophobic interactions with Asn155 and
ys156 (Table 1). Over time, the Tyr143 is turned towards the
able 1
inding interactions between DKA and HIV-1 IN (averaged over last 500ps).
IN complex Interaction energy
(kcal/mol)
Strand transfer (ST)
IC50 (M)
Hydroph
L-731,988 −128.4 0.17a I141; Y1
L-708,906 −138.9 0.10b V79, I14
S147; Q1
S-1360 −137.7 0.02c P142; P1
a Ref: [53].
b Ref: [17].
c Ref: [18].
d The nitrogen atom on the sidechain amide group of N155 also forms H-bond with L-7Fig. 4. Root-mean-square deviation (RMSD) from the starting structure of the MD
simulations, measured for all C atoms of the protein IN/DKA.
L-731,988, forming additional hydrophobic interaction (Fig. 5). The
unique orientation of Tyr143, induced by L-731,988 binding, is
favourable to form hydrophobic interaction such that it is likely
to be responsible for the potency of L-731,988.
Examining of the structure of IN in complex with L-708,906
disclosed that one aromatic ring of L-708,906 is located in the
hydrophobic face of a polar cavity formed by Asn155, Lys156
and Gln148. Over time, the catalytic residue Glu152 is pushed
away from the Mg ion and the cavity between Ile141 and
Gln146 opened, forming an adjacent hydrophobic pocket con-
taining Pro142, Asn144 and Gln146. The second aromatic ring of
L708,906 is nested nicely within the second hydrophobic cavity
(Fig. 6). Theadditionalhydrophobic interactionbetween the second
benzene ring of L-708,906with the second hydrophobic cavity thus
contributes to its higher potency in IN strand transfer, compared
with L-731,988. In addition, the nitrogen atom on the side chain
carboxamide of Asn155 forms a H-bond with the oxygen atom of
obic contacts Distance (Å)
E152-R199 K159-carboxylate or triazole
43, N155, K156 8.9 4.5
1, P142, P145, Q146,
48, N155d, K156
5.0 2.6
45, Q146, N155, K156 5.8 2.9
08,906.
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sig. 5. The interaction modes of DKA inhibitors in the active site of HIV-1 IN. The ke
ode. The surface loop (residues 138-149) is shown in pink by ribbon representatio
he ion-pair interactions between Glu152 and Arg199 are circled in orange. (A) L-73he benzyl ether group of L-708,906. Interestingly, the close contact
f DKA inhibitors with Pro145 and Gln146 and the hydropho-
ic interactions with Pro145 and Tyr143, are also observed in the
ecently resolved crystal structures of PFV IN bound with diketo-
ig. 6. The alignment of the minimized average structures (over last 500ps) of IN-L-
08,906 (green), and IN-S-1360 (violet) with IN-L-731,988 (orange). The molecular
urface of IN in complex with L-708,906 is shown in gold colour.dues are shown in tube mode and the ligand and Mg ion are shown in stick and ball
salt bridge interactions between ligands and Lys159 are marked in red circles and
(B) L-708,906 (C) S-1360.
containing HIV-1 IN drugs, Raltegravir or Elvitegravir [27]. These
DKA derived IN drugs are in van derWaals contactwith Pro214 and
Gln215 (corresponding toPro145andGln146 inHIV-1 IN), and form
hydrophobic interactions with Pro214 (corresponding to Pro145
and Tyr143 in HIV-1 IN), while the 1,3,4-oxadiazole of Raltegravir
forms – stacking interaction with Tyr212 (Tyr143 in HIV-1 IN).
Examining of the average structures of S-1360 revealed that the
phenyl group of the ligand pointed towards the hydrophobic face
of a polar cavity formed by Pro145, Gln146, Asn155 and Lys156
(Fig. S3). The hydrophobic interaction between Gln146 on the ﬂex-
ible loop and the ﬂuorobenzene ring of S-1360 is in agreementwith
previous experiment where Q146K mutation in combination with
othermutations confers resistance to S-1360 [22]. The central furan
ring of S-1360 is involved in hydrophobic contact with Pro142.
We then examined the conformational change of IN, in par-
ticular the shape of the catalytically active loop region (residues
138–149), in the IN complex structures. It was disclosed that the
loop in IN bound with L-731,988 and S-1360, had been constrained
into an extended conﬁguration, while the loop in IN bound with
L-708,906 is in a more open conformation. This conformation is
favourable for the accommodation of an additional aromatic group,
such that higher inhibitory activities have been observed for those
DKA compounds which bear an additional benzene ring at this
position (Fig. 6).In the crystal structures of apo IN (pdb code: 1BIS or 3L3U),
the distance between Thr66 and Lys159 is around 3.0 A˚, indicat-
ing a H-bond is formed. When IN is bound to 5-ClTEP (pdb code:
1QS4), the distance is increased to 3.7 A˚; much too far to form a
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itrogen atom of ligand, versus simulation time for the IN in complex with DKA
nhibitors.
-bond. In both IN-L-731,988 and IN-S-1360, Thr66 is brought
loser to Lys159, indicating that Thr66 may facilitate the DKA bind-
ng through hydrogen bonding with Lys159, which is involved in
trong salt ion interaction with the acidic part of the DKA com-
ounds (for further detail refer to the salt bridge section). This
s in agreement with mutagenesis experiments where T66I con-
ers inhibitory resistance to this compound [18,22]. However, in IN
ound with L-708,906, this H-bond is not observed.
The involvement of interaction between DKA compounds and
esidues Thr66, Gln146, Gln148, Asn155, Lys156, Lys159 of IN is
ommensurate with the previous study, where these residues have
een suggested to play important roles through affecting IN cat-
lytic activity (Table S1) or cellular DNA binding [15,16].
.5. Salt bridge interactions between the acidic part of DKAs and
ys159
The time evolution of the distance between the NZ atom of
ys159 and the carboxylate oxygen of Merck inhibitors, or the tri-
zole nitrogen atom of S-1360 is shown in Fig. 7. In the IN bound
ith 5-ClTEP structure, the distance between Lys159 and the acidic
itrogen of the tetrazole ring of 5-ClTEP is 2.8 A˚, which indicates
hat the ligand forms a salt bridge with Lys159. The distances
etween Lys159 and the acid part of the Merck inhibitors and S-
360 were examined for the conformation averaged over the last
00ps of the MD simulations. The residue Lys159 was brought in
lose proximity to the carboxylate group of L-731,988 with the dis-
ancebetween theammonianitrogenof Lys159and thecarboxylate
xygen around 4.5 A˚ in the IN-L-731,988 complex, implying only a
eak salt bridge interaction is formed. In IN bound with L-708,906,ics and Modelling 29 (2011) 956–964 961
the Lys159 was brought even closer to the carboxylate of the lig-
and and the distance between the ammonia group of Lys159 and
the carboxylate group of the ligand was shortened to 2.6 A˚, indicat-
ing a stronger salt bridge was formed. In the average structures of
IN-S-1360 complex the charged ammonia group of Lys159 moved
closer to the acidic group of S-1360, with the distance between
ammonia nitrogen and triazole nitrogen around 2.9 A˚, indicating
that a strong salt bridge interaction had formed.
Therefore, a salt bridge interaction is displayed between Lys159
and all the DKA compounds studied, regardless of whether the
acidic part is carboxylate group or heterozolate group. Also,
a stronger salt interaction was observed for the most potent
inhibitors, L-708,906andS-1360. Thuswesuggest that formationof
such salt-bridge interaction should to be responsible for the exhib-
ited inhibition activities of these compounds.
In order to assess the angular preference for the perpendicular
approach of the positively charged Lys159 to the triazole ring, the
distance between the Nz atom of Lys159 and the centroid of the
triazole ring was calculated together with the angle formed by Nz
of Lys159, the centroid of the triazole ring and N1 atom of S-1360
(Fig. S4). In the minimized average structure over the last 500ps of
simulation, the distance between the Nz of Lys159 to the centroid
of the 1, 2, 4-triazole ring is 2.9 A˚ (Fig. 5) and the angle formed
by Nz, the centroid and N1 atom of the triazole is 75◦, indicating
cation– interaction also exists for S-1360. Under the physiological
condition, S-1360appears inneutral formas its pKa is around9 [51],
therefore for the binding of neutral form of S-1360, the cation–
interaction should be the dominant interaction.
3.6. Reorientation of Glu152 to form ionic interaction with R199
and its implication on DKA competitive inhibition
We also examined the effect of inhibitor binding on the orienta-
tion of the third catalytic residue, Glu152. When IN is bound with
Merck inhibitors and S-1360, Glu152 was pushed away from the
catalytic site. When we prepared our manuscript, a high resolu-
tion HIV IN crystal structure was resolved, in which the ﬂexible
loop displays unique orientation (pdb code: 3L3U) [52]. Of par-
ticular interest is the fact that Glu152 is pointing away from the
active site, an observation which is in agreement with the reported
reorientation of Glu152 in our simulations.
The time evolution of the distances betweenGlu152 andArg199
is given in Fig. 8. Compared with the relative position of Glu152
to Arg199 in the IN crystal structure, the Glu152 in IN bound with
DKA inhibitors tends to engage an ion–pair interactionwithArg199
on 6 which is attached to the C-terminal. The distances between
OE2 of Glu152 and NH2 of Arg199 in IN-S-1360, and IN-L-708,906
are 5.8 A˚ and 5.0 A˚, respectively, implying formation of weak salt
bridge interactions (Fig. 5); In IN bound L-731,988, Glu152 is also
pushed away from the catalytic centre, but it is still too far away
from R199 to form a salt bridge interaction. The distances between
Glu152 and Arg199 in the minimized average structures over the
last 500ps of simulations are listed in Table 1. It can be seen that
the order of the distance correlates with their potency, indicating
that the formation of the additional salt bridge between Glu152
and Arg199 can greatly constrain the ﬂexibility of the surface loop
(residues 138–149) and therefore may account for their biological
activities.
We therefore propose that the salt bridge between Lys159 and
the acid group of the compounds is indispensable for the com-
pounds to exhibit inhibition activities, but the order of potency
of the DKA inhibitors depends on formation of widened loop con-
formation accompanied by formation of an additional ion–pair
interaction between Glu152 and Arg199. Since the C-terminal
domain of IN has been suggested to bind the viral DNA during the
integration process [7], forming of the salt ion interaction between
Journal Identiﬁcation = JMG Article Identiﬁcation = 6069 Date: May 6, 2011 Time: 10:6 am
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aig. 8. The distance between the carboxylate OE2 of Glu152 and NH2 of Arg199,
ersus simulation time for the IN proteins, uncomplexed or bound with DKA
nhibitors.
lu152 and Arg199 may constrain the ﬂexibility of an elbow kink
n6 which links the C-terminal to the catalytic core domain, thus
reventing the target DNA substrate from accessing the IN.
Direct interactions between the DKA compounds and another
wo residues related to inhibitor resistance (Ser153 and Met154),
ere not reported in the average structures.We suggest thatmuta-
ion of these two residues may induce a conformational change of
he active site, in particular the reorientation of Glu152, such that
he inhibition function of DKA inhibitors is interrupted.
.7. Interpretation of the strand transfer activities
We calculated the averaged interaction energies over the last
00ps of the MD simulation (Table 1). It can be seen that for
erck inhibitors, the interaction energies with IN are correlated
ell with the biological activities of DKA inhibitors. The interac-
ion energy with L-731,988, which is −128kcal/mol, is less than
hat of L-708,906, which is −139kcal/mol. The order of the inter-
ction energies of L-731,988 and L-708,906 are in agreement with
xperimental activities [53]. The interaction energy of S-1360 is
reater than that of L-731,988; however, its energy is similar to
hat of L-708,906, in contrast to the experimental observation. The
nteraction energies are not correlated very well to the binding
fﬁnities, indicating thedifference in the entropic contributiondur-
ng the binding may not be neglected. It also needs to be noted that
he interaction energies calculated here were the sum of van der
aals, Coulomb and H-bond terms, and that the cation– inter-
ction observed in S-1360 and IN is not well accounted by theics and Modelling 29 (2011) 956–964
standard force ﬁeld. So the change of free energy obtained from
experiment may be different from the interaction energies calcu-
lated here, and therefore the order of the binding afﬁnities is not
strictly correlated with the interaction energies. In saying that, the
aim of our work was to correlate the potency order, rather than
quantify thebinding energy. Theorder of the interaction energy can
be explained by the bindingmodes among different DKA inhibitors.
The aromatic groups of the Merck inhibitors L-731,988, L-708,906
and also S-1360 can ﬁtwell into the hydrophobic cavities identiﬁed
(Fig. 6). While nested in the hydrophobic cavity, the acidic part of
these compounds forms salt bridge interactionswith Lys159, there-
fore, exhibiting potent strand transfer activity. Merck inhibitor
L-731,927 [19] (Fig. 2) has a phenyl group which could be accom-
modated in the hydrophobic pocket, due to the ﬂexibility of ethyl
group. Consequentially, it has comparable strand transfer activ-
ity compared with L-731,988 and L-708,906. However, for another
Merck inhibitor with biphenyl substituent, L-731,942, the second
benzene ring is too big to be accommodated in the hydrophobic
cavity near Gln146 and as a result, its strand transfer inhibition
concentration is of higher magnitude.
4. Conclusion
The structures of HIV-1 IN in complex with several representa-
tive DKA inhibitors, namely Merck inhibitors L-731,988, L-708,906
andShionogi inhibitor S-1360,were studiedby comparativemolec-
ular dynamics simulations. We found that the acidic end of all the
DKA inhibitors studied formed favourable ionic interactions with
Lys159. The keto–enol parts of these compounds were consistently
coordinated to Mg, compatible with the putative metal sequestra-
tionmodel proposed byGrobler et al. and also the recently resolved
crystal structure of prototype foamy virus (PFV) IN bound with two
HIV-1 IN drugs. The enol oxygen of the DKA was hydrogen-bonded
to two of the catalytic residues, Asp64 and Asp116, either directly
or mediated by bridging water molecules identiﬁed throughout
the MD simulations. This is in agreement with the experimen-
tal study where D64A and D116A mutants both confer resistance
to the Merck inhibitors. The catalytic residue Glu152 formed a
favourable ion–pair interactionwith thenegatively chargedArg199
on 6, when IN is complexed with either L-708,906 or S-1360.
The complexation with Merck inhibitors and S-1360 signiﬁcantly
constrained the ﬂexible surface loop into an extended or open con-
formation. The hydrophobic contact with several residues on the
ﬂexible surface loop (residues 138–149), including Ile141, Pro142,
Asn155, as well as Gln146 and Gln148, with the aromatic ring of
Merck inhibitors and S-1360 accounted for the stabilization of the
ﬂexible active site loop.
Our result has demonstrated that the Merck inhibitors and
S-1360 share a similar IN binding mode, which involves chelat-
ing with the metal ion and forming a salt ion interaction with
Lys159. The difference in binding afﬁnities, however, may be inter-
preted by the formation of an additional salt bridge with R199,
by reorientation of the catalytic residue Glu152 effectively con-
straining the ﬂexibility of active site loop, residues 138–149. The
interaction modes of DKA inhibitors, provided here, demonstrate
that the dynamic aspects of complexation must not be ignored in
structure-based inhibitor design. A complete understanding of the
conformation adopted by the catalytic loop upon binding of DKA
inhibitors would, indeed shed light on design of novel HIV-1 IN
inhibitors.Acknowledgements
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